Panelists Mark A. Socinski, MD; Tracey L. Evans, MD; Jared Weiss, MD; and Edward S. Kim, MD, discuss their treatment considerations for patients with squamous non–small cell lung cancer who progress following first-line therapy and suggest when immunotherapy may or may not be appropriate compared to cytotoxic chemotherapy.